Clinical Trial Update: Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating panobinostat (LBH589) in addition to corticosteroids for acute graft-versus-host disease. Results were posted in 2016 after the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Graft-Versus-Host Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-12-22